Table 2. Severity, ICU management and outcomes.
| Median [IQR] or N (%) | |
| SOFA score at ICU admission | 5 [3.5–8] |
| Criteria for Acute respiratory distress syndrome * | 60 (73.2%) |
| Mild/Moderate/Severe | 4 (6.6%)/9 (15%)/47 (78.3%) |
Pulmonary hypertension (RV dysfunction) 
|
32 (40.5%) |
| Ventilatory support | |
| High flow oxygen | 77 (92.8%) |
| Non-invasive ventilation alone | 12 (14.5%) |
| Non-invasive ventilation followed by intubation | 17 (20.5%) |
| First line invasive mechanical ventilation | 33 (39.8%) |
| Treatments | |
| Antibiotics | 78 (95.1%) |
| High-dose steroids | |
| No | 29 (34.9%) |
| Yes, but with no respiratory response¥ | 22/54 (40.7%) |
| Yes, with respiratory response¥ | 32/54 (59.3%) |
| Other immunosuppressive drugs£ | 14 (16.9%) |
| Outcomes | |
| ICU length of stay | 8 [3], [14] |
| Hospital length of stay | 20 [11, 35] |
| Hospital mortality | 34 (41%) |
| 6-month mortality | 43 (52.4%) |
| 1-year mortality | 44 (53.7%) |
| Treatment-limitation decisions | 22 (26.5%) |
*ARDS was defined using Berlin criteria [2].
Pulmonary hypertension (right ventricular dysfunction) was assessed by transthoracic echocardiography (excluding left ventricular dysfunction).
¥ Responsiveness to corticosteroids was defined as an increase in the ratio of arterial oxygen saturation (PaO2) over fraction of inspired oxygen (FiO2) ratio to more than 100 mmHg within 1 week of initiating high-dose corticosteroid therapy.
£ cyclophophamide or rituximab.